Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)
China · Delayed Price · Currency is CNY 20.22
+0.54 (2.74%)
Mar 27, 2026, 4:00 PM EDT
Jiangsu CoWin Biotech Revenue
In the year 2025, Jiangsu CoWin Biotech had annual revenue of 193.05M CNY with 53.36% growth. Jiangsu CoWin Biotech had revenue of 53.47M in the quarter ending December 31, 2025, with 93.80% growth.
Revenue
193.05M
Revenue Growth
+53.36%
P/S Ratio
11.53
Revenue / Employee
231.75K
Employees
770
Market Cap
2.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 193.05M | 67.17M | 53.36% |
| Dec 31, 2024 | 125.88M | -45.47M | -26.54% |
| Dec 31, 2023 | 171.34M | -350.26M | -67.15% |
| Dec 31, 2022 | 521.60M | 183.14M | 54.11% |
| Dec 31, 2021 | 338.46M | 105.25M | 45.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Zhejiang East Asia Pharmaceutical | 831.56M |
| Guiyang Xintian Pharmaceutical | 755.34M |
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Hubei Goto Biopharm | 626.28M |
| Sailong Pharmaceutical Group | 244.84M |
| Shanghai Serum Bio-Technology | 196.21M |